An NCAA committee has made a formal recommendation to remove cannabis from their banned substances list for college athletes.
In a recent press statement (1), the National Collegiate Athletic Association (NCAA) Committee on Competitive Safeguards and Medical Aspects of Sports (CSMAS) formally announced their recommendation that cannabis should be removed from the organization’s banned substances list for college athletes. The committee also stated (10 that all three of the organization’s governing bodies should “introduce and adopt legislation that would remove cannabinoids from the list of NCAA banned drug classes.”
This recommendation reportedly comes after an extensive study informed by industry and subject matter experts. In December 2022, the NCAA also hosted a Summit on Cannabinoids in College Athletics (2). The consensus opinion formed at that event was that cannabis was not a performance-enhancing drug and that a harm-reduction approach to cannabis would be best implemented at the school level.
The NCAA statement reads (1): “In short, removing cannabinoids from the list of banned substances:
"When making a decision on an important topic like this, we agree that the membership should have an opportunity to vote on the final outcome," said James Houle, committee chair and lead sport psychologist at Ohio State (1). "We are recommending a big shift in the paradigm when it comes to cannabinoids. We want to modernize the strategy with the most up-to-date research to give schools the best opportunity to support the health of student-athletes."
The exact timing of discussion and adoption of possible legislation is a decision that will be made by each of three NCAA divisional governance structures (1).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.